Showing results (31-40 of 447) with videos related to
Sort By:
Pageof 45
Clinical Lung Cancer|July 30, 2024
Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After ChemoradiotherapySaori Murata, Hidehito Horinouchi, Momoko Morishita, et al.Cancer Immunology, Immunotherapy : CII|April 16, 2023
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterationsYukiko Shimoda, Tatsuya Yoshida, Jun Miyakoshi, et al.Journal of Thoracic Disease|August 30, 2019
Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysisKen Masuda, Yutaka Fujiwara, Yuki Shinno, et al.Current Problems in Cancer|April 4, 2025
Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failureYoh Yamaguchi, Yuki Shinno, Ken Masuda, et al.Thoracic Cancer|January 14, 2025
Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical OutcomesKen Masuda, Tatsuya Yoshida, Noriko Motoi, et al.JTO Clinical and Research Reports|April 3, 2023
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLCHitomi Jo, Tatsuya Yoshida, Shigehiro Yagishita, et al.Scientific Reports|September 22, 2021
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertionsChie Morita, Tatsuya Yoshida, Masayuki Shirasawa, et al.Lung Cancer (Amsterdam, Netherlands)|April 9, 2022
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysisMasahiro Torasawa, Tatsuya Yoshida, Shigehiro Yagishita, et al.Cancer Medicine|April 16, 2023
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patientsMasahiro Torasawa, Tatsuya Yoshida, Yuki Takeyasu, et al.Anticancer Research|November 4, 2021
Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer PatientsYukiko Shimoda, Tatsuya Yoshida, Masayuki Shirasawa, et al.Pageof 45